[關(guān)鍵詞]
[摘要]
目的 研究內(nèi)皮抑素-力達(dá)霉素輔基蛋白融合蛋白(ES-LDP)對(duì)人乳腺癌、胰腺癌和食管癌組織的靶向性。方法 分別采用人體乳腺癌、胰腺癌和食管癌組織芯片,利用免疫組化的方法,研究ES-LDP與癌細(xì)胞的親和力;并采用Image-Pro Plus6.0 軟件計(jì)算吸光度值,進(jìn)行統(tǒng)計(jì)分析。結(jié)果 與輔基蛋白比較,ES-LDP 對(duì)乳腺癌、胰腺癌和食管癌親和力顯著增高(P <0.001)。在胰腺癌組織,這種親和力也顯著高于對(duì)正常組織的親和力(P <0.05)。結(jié)論 ES-LDP 對(duì)不同組織器官,親和力有所不同;在進(jìn)行體內(nèi)抗腫瘤活性評(píng)價(jià)時(shí)要注意選擇合適的模型。
[Key word]
[Abstract]
Objective To study the targeting activity on human breast cancer, pancreatic cancer, and esophageal cancer of endostatin-lidamycin fusion protein (ES-LDP). Methods Multiple tissue microarrays of breast cancer, pancreatic cancer, and esophageal cancer were used. ES-LDP and its affinity was studied by immunohistochemical way. Additionally, the cases were analyzed by Image-Pro Plus 6.0 software. The absorbance was log transformed and mainly performed statistical analysis. Results ES-LDP had higher affinity than LDP to breast cancer, pancreatic cancer, and esophageal cancer (P < 0.001). Additionally, the affinity of ES-LDP to pancreatic tumor was higher than that of normal pancreatic tissue (P < 0.05). Conclusion The binding activity of ES-LDP is different to kinds of tissues. The suitable models are necessary to investigate its antitumor activity in vivo.
[中圖分類號(hào)]
[基金項(xiàng)目]
國家自然科學(xué)基金資助項(xiàng)目(81450049);山東省醫(yī)藥衛(wèi)生科技發(fā)展計(jì)劃資助項(xiàng)目(2014WS0486)
